Cargando…

The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients

PURPOSE: To assess the biological variability of clinical meaningful molecular markers and their clinical correlations in Chinese patients with colorectal cancer (CRC). MATERIALS AND METHODS: In this prospective observational study, frequencies and clinico-pathological features of RAS and BRAFV600E...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Junjie, Huang, Dan, Poston, Graeme, Ma, Xiaoji, Wang, Renjie, Sheng, Weiqi, Zhou, Xiaoyan, Zhu, Xiaoli, Cai, Sanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564750/
https://www.ncbi.nlm.nih.gov/pubmed/28416767
http://dx.doi.org/10.18632/oncotarget.16176
_version_ 1783258294775709696
author Peng, Junjie
Huang, Dan
Poston, Graeme
Ma, Xiaoji
Wang, Renjie
Sheng, Weiqi
Zhou, Xiaoyan
Zhu, Xiaoli
Cai, Sanjun
author_facet Peng, Junjie
Huang, Dan
Poston, Graeme
Ma, Xiaoji
Wang, Renjie
Sheng, Weiqi
Zhou, Xiaoyan
Zhu, Xiaoli
Cai, Sanjun
author_sort Peng, Junjie
collection PubMed
description PURPOSE: To assess the biological variability of clinical meaningful molecular markers and their clinical correlations in Chinese patients with colorectal cancer (CRC). MATERIALS AND METHODS: In this prospective observational study, frequencies and clinico-pathological features of RAS and BRAFV600E mutations, deficiency of DNA mismatch repair (dMMR) were evaluated in patients with colorectal cancer staged I-IV. The molecular heterogeneity between right-sided and left-sided colorectal cancers was studied in our series by classifying patients with different mutations and dMMR status. RESULTS: Among 400 evaluable patients, mutations in KRAS exon 2, exon 3 or 4, NRAS and BRAFV600E were detected in 36%, 7.5%, 3.5% and 2.5%, respectively. RAS mutations were significantly higher in metastatic CRCs (56.4% vs. 43.1%, p=0.015) and right-sided CRCs (62.5% vs 41.7%, p=0.003). In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer. CONCLUSIONS: By assessing the mutations and clinical correlations of RAS and BRAF genes, and dMMR status, similar RAS mutation, dMMR frequency and lower BRAF mutation was observed in Chinese patients compared to western patients. A distinct molecular heterogeneity was found between patients with right-sided and left-sided CRCs.
format Online
Article
Text
id pubmed-5564750
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55647502017-08-23 The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients Peng, Junjie Huang, Dan Poston, Graeme Ma, Xiaoji Wang, Renjie Sheng, Weiqi Zhou, Xiaoyan Zhu, Xiaoli Cai, Sanjun Oncotarget Research Paper PURPOSE: To assess the biological variability of clinical meaningful molecular markers and their clinical correlations in Chinese patients with colorectal cancer (CRC). MATERIALS AND METHODS: In this prospective observational study, frequencies and clinico-pathological features of RAS and BRAFV600E mutations, deficiency of DNA mismatch repair (dMMR) were evaluated in patients with colorectal cancer staged I-IV. The molecular heterogeneity between right-sided and left-sided colorectal cancers was studied in our series by classifying patients with different mutations and dMMR status. RESULTS: Among 400 evaluable patients, mutations in KRAS exon 2, exon 3 or 4, NRAS and BRAFV600E were detected in 36%, 7.5%, 3.5% and 2.5%, respectively. RAS mutations were significantly higher in metastatic CRCs (56.4% vs. 43.1%, p=0.015) and right-sided CRCs (62.5% vs 41.7%, p=0.003). In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer. CONCLUSIONS: By assessing the mutations and clinical correlations of RAS and BRAF genes, and dMMR status, similar RAS mutation, dMMR frequency and lower BRAF mutation was observed in Chinese patients compared to western patients. A distinct molecular heterogeneity was found between patients with right-sided and left-sided CRCs. Impact Journals LLC 2017-03-14 /pmc/articles/PMC5564750/ /pubmed/28416767 http://dx.doi.org/10.18632/oncotarget.16176 Text en Copyright: © 2017 Peng et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Peng, Junjie
Huang, Dan
Poston, Graeme
Ma, Xiaoji
Wang, Renjie
Sheng, Weiqi
Zhou, Xiaoyan
Zhu, Xiaoli
Cai, Sanjun
The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
title The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
title_full The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
title_fullStr The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
title_full_unstemmed The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
title_short The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients
title_sort molecular heterogeneity of sporadic colorectal cancer with different tumor sites in chinese patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564750/
https://www.ncbi.nlm.nih.gov/pubmed/28416767
http://dx.doi.org/10.18632/oncotarget.16176
work_keys_str_mv AT pengjunjie themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT huangdan themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT postongraeme themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT maxiaoji themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT wangrenjie themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT shengweiqi themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT zhouxiaoyan themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT zhuxiaoli themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT caisanjun themolecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT pengjunjie molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT huangdan molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT postongraeme molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT maxiaoji molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT wangrenjie molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT shengweiqi molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT zhouxiaoyan molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT zhuxiaoli molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients
AT caisanjun molecularheterogeneityofsporadiccolorectalcancerwithdifferenttumorsitesinchinesepatients